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Abstract (248 words) 1 
Objective 2 
To explore factors associated with adherence to antihypertensive drugs overall 3 
³WKHUDS\ DGKHUHQFH´ DQG WR particular classes (³FODVV DGKHUHQFH´ in hypertensive 4 
patients.  5 
 6 
Methods 7 
This retrospective cohort study included adults with primary hypertension identified in 8 
the UK Clinical Practice Research Datalink from April/2006 to March/2013. Individuals 9 
were followed from the date of first-ever antihypertensive drug class (class adherence) 10 
prescribed and from the date of the first-ever antihypertensive drug (therapy 11 
adherence) issued to the earliest of study end, patient leaving the database or death. 12 
Prescribing episodes (time from a drug class being first prescribed to the end of follow-13 
up time) of six antihypertensive drug classes were recorded. Proportion of Days 14 
Covered (PDC) was used to estimate therapeutic adherence for D SDWLHQW¶V 15 
antihypertensive drugs therapy during follow-up period and class adherence of a 16 
specific antihypertensive class in each episode, respectively. Generalized linear 17 
modelling was used to examine factors associated with PDC. 18 
 19 
Results 20 
Median therapy and class PDC were 93.9% and 98.3% in the 176,835 patients and 21 
371,605 prescribing episodes; 20% and 38.4% of the patients and episodes had 22 
PDC<80%, respectively. Higher therapy and class PDC was associated with increasing 23 
age, using renin angiotensin drugs and being pre-existing patient and user of 24 
antihypertensive drugs. Higher deprivation, multiple comorbidities and switching of 25 
antihypertensive drugs were associated with lower PDC. 26 
 27 
4 
Conclusions 28 
Several patient factors were confirmed as determinant of adherence to 29 
antihypertensive drug classes and therapy; hence they can assist in identifying patients 30 
at risks of non-adherence; thus targeting them for adherence improving interventions. 31 
 32 
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5 
Introduction 38 
Hypertension (HT) is a highly prevalent condition in the United Kingdom (UK) with an 39 
estimated prevalence of 13.7% [1]. Antihypertensive drugs have been shown to reduce the 40 
risk of cardiovascular complications, premature mortality [2] and achieve cost-savings [3] in 41 
people with HT. Nevertheless, suboptimal control of BP has been consistently reported in 42 
population-based surveys of hypertension management worldwide [4, 5] .  43 
 44 
PDWLHQWV¶poor adherence to antihypertensive drugs is considered one of the key contributing 45 
factors to suboptimal BP control [6]. Long-term adherence to antihypertensive therapy is 46 
crucial to achieve and maintain optimal BP control [7]. Reported adherence to 47 
antihypertensive drugs varies from 28% to 78% [8, 9], attributed mostly to differences in 48 
study populations, types of medications being considered, study designs, follow-up time, and 49 
definitions and measurement of adherence. 50 
 51 
Poor adherence to antihypertensive drugs is associated with increased cardiovascular 52 
events and hospitalisations with subsequently high costs and healthcare resources utilisation 53 
[10, 11]. In England, the estimated potential cost of the health gains foregone as a result of 54 
non-adherence to antihypertensive drugs is about £390 million per annum [12]. It was also 55 
estimated that over £100 million per annum would be saved if 80% of people with 56 
hypertension were adherent to their medications [12]. 57 
 58 
Understanding factors associated with adherence is crucial for patients, and healthcare 59 
professionals and providers. Previous studies have found associations between adherence 60 
to antihypertensive drug therapy and factors such as patients¶ age, gender, comorbidity and 61 
type of antihypertensive drug class [8, 9], however, the joint impact of these factors have not 62 
been evaluated together in a single cohort.   63 
 64 
6 
Most studies assessed adherence to antihypertensive drug classes in patients with newly-65 
diagnosed hypertension [13]. Patients with pre-existing hypertension are expected to have 66 
different medication-taking behaviours compared with newly-diagnosed patients [13]. The 67 
LPSDFW RI VZLWFKLQJ IURP RQH DQWLK\SHUWHQVLYH GUXJ FODVV WR DQRWKHU RQ D SDWLHQW¶V68 
adherence to overall antihypertensive drug therapy (therapy adherence) as well as to a 69 
particular antihypertensive drugs class (class adherence) has not been widely studied [8, 9]. 70 
Assessing adherence to individual antihypertensive drug classes without considering 71 
adherence to overall antihypertensive drug therapy limits the applicability of research 72 
findings from most previous studies as the majority of hypertensive patients are prescribed 73 
more than one antihypertensive drug class for their BP control [2]. Many studies have 74 
transformed adherence into a binary variable, using a cut-off point of 80%. Furthermore, a 75 
simple binary measure for adherence [8, 14] assumes patients over a wide range of 76 
adherence values (PDC 0-80%) to have same medication-taking behaviour, and thus may 77 
SRWHQWLDOO\PLVFODVVLI\PLVMXGJHDSDWLHQW¶VDGKHUHQFHEHKDYLRXU 78 
 79 
These factors limit the application and generalisability of previous study results to patient 80 
medicine-taking behaviour in real practice. To add to what is known about adherence in 81 
hypertension, this study assessed the association between patient characteristics and 82 
adherence to both overall antihypertensive therapy and individual drug classes by applying a 83 
robust analytical method to analyse adherence as a continuous variable in patients with both 84 
newly diagnosed and pre-existing primary hypertension as an approach to produce more 85 
accurate and generalisable findings. 86 
 87 
Methods 88 
Study design and data source 89 
This retrospective cohort study used data from the UK Clinical Practice Research Datalink 90 
(CPRD) database [15] from April 2006 to March 2013, as it was the most updated date for 91 
the availability of CPRD data at the time of the study. CPRD is a primary care database 92 
7 
containing longitudinal electronic clinical data of more than 13.7 million patients including 93 
LQIRUPDWLRQ DERXW SDWLHQWV¶ GHPRJUDSKLFV PHGLFDO FRQGLWLRQV GLDJQRVHV SUHVFULEHG94 
medications, vaccination and laboratory tests. By March 2015, CPRD included 5.4 million 95 
active patients from 685 primary care practices across the UK [16]; it covers about 8.5% of 96 
the UK population and is considered to be broadly representative in terms of patient and 97 
practice characteristics [17]. This study protocol was approved by the Independent Scientific 98 
Advisory Committee of CPRD database (protocol number 13_150).  99 
 100 
Study cohort 101 
Adults (18 years old) with a diagnosis of primary hypertension and at least two 102 
antihypertensive drug prescriptions after the diagnosis date during the study period were 103 
included in this study. Included patient needed to have at least one year of CPRD records 104 
before and after the date of their first-ever antihypertensive drug prescription (index date) 105 
during the study period. Sporadic users who were prescribed only one antihypertensive 106 
prescription were excluded [13]. In order to ensure that treating hypertension is at least one 107 
of the potential indications of the prescribed antihypertensive drugs, participants were 108 
required to have their antihypertensive drugs prescribed on or after their hypertension 109 
diagnosis date.  110 
 111 
Patients with history of cardiovascular diseases (CVDs) prior to the index date were 112 
excluded because the presence of CVDs may affect the choice of antihypertensive drugs 113 
(indication bias) and SDWLHQWV¶PHGLFDWLRQ-taking behaviours (i.e., higher adherence as they 114 
are more willing to follow medical instructions) [18, 19]. Patients who were initiated on 115 
multiple antihypertensive drugs (either as fixed-dose combination or multiple pills) on the 116 
index date were also excluded as it was not possible to assign patients into a particular 117 
DQWLK\SHUWHQVLYHGUXJFODVVZKLFKLQWXUQFRQIOLFWHGZLWKWKHVWXG\¶VREMHFWLYHRIPHDVXULQJD118 
SDWLHQW¶VDGKHUHQFHWRDQ\DQWLK\SHUWHQVLYHGUXJWKHUDS\,QGHHGWKHVHSDWLHQWVKDYHRIWHQ119 
been excluded from previous adherence studies as they were reported to be at high risk of 120 
8 
HT-related complications, having higher BP value and hence would have different 121 
medication-taking behaviours [2, 20, 21]. 122 
 123 
Measurement of adherence 124 
Individuals in the cohort were followed from the index date to the earliest of: study end date, 125 
patient transferred out of the dataset (e.g. left WKHSUDFWLFH RU SDWLHQW¶VGHDWK; during this 126 
period, all antihypertensive prescriptions issued were retrieved and the duration of each 127 
prescription was calculated. Antihypertensive drugs were further divided into six classes: 128 
angiotensin-converting enzyme inhibitors (ACEIs), calcium-channel blockers (CCBs), 129 
diuretics, angiotensin receptor blockers (ARBs), beta-EORFNHUV%%VDQG³2WKHUV´including 130 
vasodilators, centrally acting drugs, alpha-blockers). 131 
 132 
A commonly used adherence measure [22], Proportion of Days Covered (PDC), was used 133 
as a µproxy¶ for adherence in this study, and both antihypertensive µtherapy adherence¶ and 134 
µclass adherence¶ were measured. Individual patients¶ adherence to any antihypertensive 135 
drug therapy (PDC for therapy adherence) during the study period was calculated by dividing 136 
the µtotal number of days covered with any antihypertensive drug¶ by the µnumber of days in 137 
the follow-up period¶ [22]. Likewise, adherence to a specific antihypertensive drug class 138 
(PDC for class adherence) in each prescribing episode of a class was calculated by dividing 139 
the µtotal number of days covered with an antihypertensive class¶ by the µnumber of days in a 140 
prescribing episode of that class¶.  141 
 142 
The prescribing episode for a class was the duration when a patient was consecutively 143 
prescribed with the same antihypertensive drug class, starting from the date of a patient¶s 144 
first-ever prescription of the class during study period to the final date covered by the 145 
antihypertensive class. Multiple episodes can be identified in one SDWLHQW¶s follow-up period, 146 
as patients may discontinue or switch to other drug classes. 147 
 148 
9 
Study covariates 149 
Baseline characteristics of patients, including SDWLHQWV¶ GHPRJUDSKLFV DJH JHQGHU DQG150 
socioeconomic status), disease status (comorbidity, hypertension status) and their drug use 151 
status (type of antihypertensive drug class, antihypertensive drug use status [pre-existing or 152 
new users]) on the index date were included as covariates that may be associated with 153 
patients¶ adherence. Furthermore, whether patients have been switched from their 154 
antihypertensive drug class was also included as a study covariate. To account for the 155 
YDULDWLRQVLQSDWLHQWV¶IROORZXSWLPHwhich UHVXOWHGIURPGLIIHUHQFHVLQSDWLHQWV¶VWXG\HQWU\156 
DQG H[LW GDWHV LQGLYLGXDO SDWLHQW¶V IROORZ XS WLPH ZDV LQFOXGHG DV D FRYDULDWH LQ WKH157 
regression model both as a continuous and as a categorical variable. 158 
 159 
Townsend deprivation score [23] ranging from one to five (one being least deprived and five 160 
most deprived) was used a proxy for individual patients¶ socioeconomic status (SES). 161 
Individual¶s comorbidity status was measured by the Charlson comorbidity index (CCI) [24]. 162 
Hypertension status, i.e. pre-existing (prevalent) or newly-diagnosed (incident) hypertension 163 
was judged by whether a patient had any hypertension-related diagnosis codes in the year 164 
prior to the first hypertension diagnosis code identified during the study period [25].  165 
 166 
Similarly, antihypertensive drug use status, i.e. pre-existing (prevalent) or new (incident) 167 
users of a specific antihypertensive class was judged by whether any antihypertensive class 168 
was issued in the year prior to the index prescription date identified during the episode. 169 
Switching was defined as stopping the initial antihypertensive class and starting another 170 
class. 171 
 172 
Data analysis 173 
Descriptive statistics were used to describe patient-related factors at baseline. Mean with 174 
standard deviation (SD) and median with interquartile range (IQR) were used to present 175 
normally and non-normally distributed continuous variables, respectively; proportion was 176 
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used to present categorical variables. The association between individual patient 177 
characteristics and the non-normally distributed PDC was first tested in non-parametric 178 
univariate analyses, including 6SHDUPDQ¶V UDQN FRUUHODWion test for continuous variables 179 
(age, follow-up time), Wilcoxon rank sum (Mann-Whitney) and Kruskal-Wallis tests for binary 180 
and categorical variables. 181 
 182 
The influence of all study covariates on therapy and class adherence was assessed by using 183 
two generalised linear models (GLM) with gamma family and log link function, with the 184 
dependent variable as µPDC for antihypertensive drug therapy¶ and µPDC for each episode of 185 
antihypertensive classes¶ UHVSHFWLYHO\. The results were presented as regression 186 
coefficients and 95% confidence interval (95%CI). The modelV¶ goodness of fit, in terms of 187 
the appropriateness of the chosen family and link function, was checked using the modified 188 
Park test [26] and Pregibon Link test [27]. 189 
 190 
11 
Results 191 
Baseline characteristics 192 
Overall, 176,835 adults with primary hypertension were included in this study with 371,605 193 
prescribing episodes of the six antihypertensive classes identified during the follow-up 194 
period. The mean age of patients at baseline was 60.8±13.6 years, 55.6% (n=98,320) were 195 
female, 53.4% (n=94,430) were newly diagnosed hypertensive patients and 51.0% 196 
(n=90,186) were new users of antihypertensive drugs. The median follow-up duration was 197 
5.3 (IQR: 3.1, 6.5) years. Of the 371,605 prescribing episodes, the most commonly 198 
prescribed class episodes were ACEIs (29.7%) and CCBs (25.1%). PDWLHQWV¶characteristics 199 
and drug use status were significantly different across the episodes of six antihypertensive 200 
classes (Table 1). 201 
 202 
Proportion of days covered 203 
Both individual patients¶ PDCs for antihypertensive drug therapy overall (Figure 1) and PDCs 204 
for antihypertensive class in each episode (Figure 2) were not normally distributed. Although 205 
the median PDC was 93.3% (IQR: 47.3%, 100%) and 98.3% (IQR: 86.5%, 100%) for 206 
therapy and class adherence, respectively; 20.0% of patients¶ WKHUDSHXWLF adherence and 207 
38.4% of prescribing episodes¶ FODVV DGKHUHQFH were suboptimal (PDC<80%). Mean 208 
therapy and class adherence was 87%±22.2 and 73%±33.8, respectively.  209 
 210 
Univariate analyses of factors influencing adherence 211 
The univariate analyses demonstrated that all the covariates were significantly associated 212 
with PDC for therapy adherence in the study cohort and with PDC for class adherence in 213 
each episode (Table 2). Patients who were initiating antihypertensive therapy on CCBs had 214 
the highest PDC for therapy adherence (median: 98.6%, IQR: 86.5%, 100%). On the other 215 
hand, the median PDC for class adherence in the prescribing episodes of ARBs (median: 216 
97.4%, IQR: 74.2%, 100%) was the highest amongst all antihypertensive drug classes, 217 
followed by ACEIs (median: 95.7%, IQR: 51.3%, 100%). 218 
12 
Both higher therapy and class PDCs were associated with increasing age, lower deprivation, 219 
prevalent drug users, and higher comorbidity index (CCI2). Male gender, being pre-existing 220 
hypertensive patient were associated with higher PDCs in the episodes of antihypertensive 221 
classes but lower PDCs for patients¶ overall therapy adherence. Switching between 222 
antihypertensive drug classes was also associated with lower PDC for therapy adherence. 223 
 224 
Multivariate analyses of factors influencing adherence 225 
The results from the GLM analysis indicated that all the patient characteristics were 226 
independent factors for both patients¶ adherence to antihypertensive therapy and to a 227 
specific drug class in each episode (Table 3). 228 
 229 
Being female, having pre-existing hypertension, previous utilisation of antihypertensive 230 
PHGLFLQHV DQG ROGHU DJH ZHUH DVVRFLDWHG ZLWK KLJKHU 3'& IRU SDWLHQWV¶ DQWLK\SHUWHQVLYH231 
therapy; on the other hand, higher deprivation index, high comorbidity scores (CCI2), and 232 
switching of antihypertensive drug class were assoFLDWHG ZLWK ORZHU 3'& RI SDWLHQWV¶233 
antihypertensive therapy. Patients who were initiated with ACEIs and ARB as the index drug 234 
class during the study period; their PDCs for therapy adherence significantly increased by 235 
4% and 3% (p<0.001), respectively. 236 
 237 
Similarly, pre-existing hypertension, pre-existing antihypertensive drug user, and older age 238 
were also associated with a higher PDC for class adherence in each episode; on the other 239 
hand, being female, higher deprivation index, and high comorbidity scores (CCI2) were 240 
associated with lower a PDC for class adherence. Comparing between different 241 
antihypertensive drug classes, the highest PDC was in the episodes started from ARBs 242 
(13%, p<0.001), followed by ACEIs (8%, p<0.001); and the PDC for class categories 243 
³2WKHUV´ZDVWKHORZHVWS 244 
 245 
13 
%RWKFODVVDQGWKHUDS\3'&VVLJQLILFDQWO\FKDQJHGRYHUSDWLHQWV¶IROORZ-up time. There was 246 
a significant declining trend in class PDC across follow-up time categories with an average 247 
decline of 1.4% for each year increase in follow up time. Whereas for therapy PDC, although 248 
WKHUH ZDV DQ DYHUDJH LQFUHDVH RI SDWLHQWV¶ DGKHUHQFH WR DQ\ DQWLK\SHUWHQVLYH WKHUDS\ E\249 
0.7% for each year increase in follow up time, the effect across follow up time categories 250 
were different. 251 
 252 
The fitted multivariate GLM regression models can predict both the mean therapy and class 253 
PDCs for any patient with a particular set of characteristics included in the model. For 254 
instance, the predicted mean PDC of diuretics in the episodes for a 50-year old, female 255 
patient, with a deprivation index of 2 and comorbidity score 2, having diuretics as the index 256 
antihypertensive drug class, being a new antihypertensive drug user, having pre-existing 257 
hypertension, and four years of follow-up time, is 67.7% (95%CI: 66.8%, 69.5%).258 
14 
Discussion 259 
Main findings 260 
This study assessed adherence to both individual antihypertensive drug classes and overall 261 
antihypertensive therapy using longitudinal data over a seven-year period.  To our 262 
knowledge, this study is the only study that has collectively analysed adherence, as a 263 
continuous variable, to both antihypertensive drug classes and overall therapy over a long 264 
period in a population of both new and existing hypertensive patient; thus providing 265 
generalisable findings by overcoming the aforementioned limitations of the previous studies. 266 
Although no similar studies were found for direct comparison of the study findings, the 267 
findings were compared with results from various studies. Overall findings are not dissimilar 268 
to these earlier studies, but now we can more confidently describe adherence behaviours in 269 
both incident and prevalent populations and better understand the relationship between 270 
individual drug class and overall therapy adherence.  271 
 272 
The median PDC at first glance may appear generally high, but the other summary 273 
measures, despite their limitations, (such as mean and proportion with PDC<80%) 274 
demonstrated a sub-optimal PDC level that is comparable with other adherence studies [22]. 275 
The overall mean PDC for antihypertensive drug class in each prescribing episode was 73% 276 
and about 40% episodes had PDC<80%. Although these results are comparable with the 277 
mean class adherence of 67% and PDC<80% of 36% reported by a systematic review of 278 
139 observational studies of adherence to antihypertensive drug classes [28], the follow-up 279 
time over which adherence was measured in the systematic review was only one year which 280 
provided limited insights into the dynamic nature of adherence beyond one year. However, 281 
this current study examined adherence over seven years and has provided deeper 282 
understanding of SDWLHQWV¶ EHKDYLRXUV LQ taking their antihypertensive medications. Class 283 
adherence declined steadily, unlike therapy adherence that showed a different pattern 284 
consisting of significant reduction in the early course of therapy (>2-3 years), followed by 285 
insignificant change (>3-5 years) then a significant increase afterward (>5 years). 286 
15 
 287 
Furthermore, a recent observational study, assessing DVVRFLDWLRQ EHWZHHQ SDWLHQWV¶ 288 
characteristics and adherence to overall antihypertensive drug therapy, also reported a 289 
similar high, overall median adherence to overall antihypertensive drug therapy of 96%, with 290 
more than 75% being considered adherent (PDC80%) [29], however, again this study was 291 
limited by short follow-up of one year as well as analysing adherence as a binary variable.   292 
 293 
)DFWRUVDVVRFLDWHGZLWKSDWLHQWV¶DGKHUHQFH 294 
Medications and clinically related factors 295 
Type of antihypertensive drug class was a significant predictor for adherence to both 296 
antihypertensive drug classes and therapy; ARBs followed by ACEIs were associated with 297 
the highest-class adherence, while diuretics and BBs were associated with the lowest. This 298 
confirms the historical findings from many other adherence studies [21, 30, 31], which has 299 
been attributed largely to the more favourable tolerability profile of ARBs and ACEIs 300 
compared with other antihypertensive drug classes. However, once switching was 301 
considered in measuring adherence to overall antihypertensive drug therapy, ACEIs rather 302 
than ARBs had the highest adherence, with BBs no longer having lower adherence 303 
compared with diuretics. This implies that all the previous historical findings were indeed 304 
biased by not considering switching in measuring adherence, especially given the better 305 
tolerability of ARBs compared with others [31], and hence less switching and better 306 
adherence profile of ARBs if switching was not considered.  307 
 308 
Lower adherence to antihypertensive drug classes and therapy was observed in newly 309 
diagnosed hypertensive patients and new antihypertensive drug users. Differences in 310 
beliefs, perceptions and attitudes towards hypertension and antihypertensive drug therapy 311 
between incident and prevalent patients could explain the observed disparity in adherence 312 
behaviour between these two groups of patients since prevalent patients may have passed 313 
the stages of lack of belief in the necessity of treating hypertension [32]. Furthermore, 314 
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SDWLHQWV¶ FRQFHUQV DQG IHDUV about antihypertensive drugs¶ adverse effects in the early 315 
stages of treatment in the case of incident patients may act as a barrier of adherence to 316 
antihypertensive drugs, particularly when patients¶ hold the belief that a drug¶s side effects 317 
outweigh any potential future benefits [33]. 318 
 319 
This study found a negative association between adherence to antihypertensive drug 320 
classes/therapy and presence of comorbidities. It has been reported that patients with no 321 
comorbidity were 29% more likely to be adherent compared with those with a high 322 
comorbidity score [34]. The negative association between high comorbidity and adherence 323 
could be partly explained by comorbidity-related polypharmacy, as additional medications 324 
are needed in response to increasing comorbid conditions [35], which has been found to 325 
decrease adherence [36]. Importantly, it appears that this has to exceed a limit before 326 
comorbidities having any negative impact of adherence, as it is evident by the fact that both 327 
class and therapy adherence were decreasing only for patients with high comorbidity score 328 
(CCI2). 329 
 330 
In previous studies [7, 37], switching between antihypertensive drug classes was associated 331 
with lower adherence to any antihypertensive drug therapy. This association could be related 332 
to many switching-related concerns WKDW ZRXOG SRWHQWLDOO\ GHFUHDVH SDWLHQWV¶ DGKHUHQFH, 333 
such as changes in product packaging and tablet appearance [38] and taste [35], differences 334 
in adherence profiles of the various antihypertensive drug classes [8]DQGLPSDLULQJSDWLHQW¶V335 
confidence in drug therapy [39] )XUWKHUPRUH LW KDV EHHQ VKRZQ WKDW SDWLHQWV¶ FRQFHUQV336 
about switching may produce a nocebo effect LHSDWLHQWV¶ negative perceptions may cause 337 
negative outcomes) [40]. 338 
 339 
Demographic factors  340 
Patients¶ demographics, such as age, gender and SES, were also significant predicators for 341 
antihypertensive drug adherence. Poor SES has been recognised by the WHO as one of the 342 
17 
SRWHQWLDO IDFWRUV IRU SDWLHQWV¶ QRQ-adherence to antihypertensive drugs [41]. An American 343 
cohort study has found that LQFUHDVLQJLQSDWLHQWV¶LQFRPHTXLQWLOHDVDSUR[\IRU6(6Zas 344 
associated with a 10% increase in the proportion of adherent patients (OR: 1.10, 95%CI: 345 
1.08, 1.12) [34]. Furthermore, a recent retrospective cohort study, which included more than 346 
30,000 adult patients, assessed WKH DVVRFLDWLRQ EHWZHHQ SDWLHQWV¶ FKDUDFWHULVWLFV DQG347 
medication adherence across eight diseases, including hypertension, and found a higher 348 
adherence level in those living in higher SES (lower deprivation) [29].  349 
 350 
Females, in general, have been consistently shown to be less adherent to antihypertensive 351 
drug classes [29, 42, 43]. Although similar finding was observed in the current study, 352 
importantly this was not the case for adherence to antihypertensive drug therapy as females 353 
had higher adherence than males. This could be explained by not allowing/considering 354 
switching in measuring adherence to antihypertensive drug classes, especially giving the 355 
higher switching rates in females [44]; i.e., once patients have been switched to another 356 
antihypertensive drug class they were considered as non-adherent to the initial drug class by 357 
definition as they have stopped taking it, but obviously patients have been adherent to the 358 
antihypertensive drug therapy overall as they continued to take the new drug class while 359 
stopped the initial class. This demonstrates how insights LQWR SDWLHQWV¶ PHGLFDWLRQ WDNHQ 360 
behaviours could be biased by purely measuring adherence to antihypertensive drug classes 361 
without considering the overall antihypertensive drug therapy, which is more influential on 362 
controlling BP.  363 
 364 
Strengths and limitations 365 
One of the major strengths of the current study is analysing adherence as a continue 366 
measure by applying an advanced statistical technique (GLM) unlike most of the previous 367 
studies [8, 9] which measured and analysed adherence as a binary variable using a non-368 
empirical, arbitrary cut-off point of 80% [8, 14]. Dichotomisation of adherence simplifies 369 
statistical analysis, presentation and interpretation of results [45] but incurs several 370 
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disadvantages. Dichotomisation of a continuous variable is often associated with loss of 371 
information [46] that can lead to loss of both estimation efficiency and power in hypothesis 372 
testing [45, 47] due to a reduction in the number of degrees of freedom [48]. Furthermore, 373 
although the 80% cut-off point for optimal adherence has been generally used and linked 374 
with clinical outcomes in previous studies, the optimal adherence cut-off point may be higher 375 
than 80%, as BP has found to continuously reduce with increases in adherence from 80% to 376 
100% [49]. 377 
 378 
Therefore, the International Society for Pharmaceutical and Outcomes Research [48] has 379 
recommended against converting continuous adherence data into binary data. On a related 380 
notes, previous studies [50, 51] that analysed adherence as a continuous measure have 381 
used inappropriate statistical methods to perform the analysis such as ordinary least square 382 
(OLS) regression. OLS is considered an inappropriate method because it requires a 383 
normally distributed outcome variable that is almost violated by the skewed distribution of the 384 
continuous adherence measure. 385 
 386 
Another main strength of this study lies in measuring adherence to both antihypertensive 387 
drug classes and any antihypertensive drug therapy using a large population dataset of both 388 
incident and prevalent hypertensive patients over a long period. Furthermore, applying an 389 
advanced statistical technique (GLM) to analyse the association between adherence (as a 390 
continuous variable) with a wide range of patient related factors. This approach has not been 391 
observed in previous adherence studies and rendered the findings more generalisable to the 392 
wider hypertensive population. For instance, measuring adherence to both antihypertensive 393 
drug classes and any antihypertensive drug therapy has increased the applicability of the 394 
study findings to the real-world management of hypertension, given the increased proportion 395 
of hypertensive patients who are prescribed more than one antihypertensive drug classes to 396 
control their BP [2]. 397 
 398 
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Furthermore, failure to allow for switching in measuring class adherence in previous studies, 399 
implies that the patient failed to take the drug as recommended [9], which, in fact, may not 400 
be the case because SDWLHQW¶VVZLWFKLQJLVRIWHQ recommended by physicians in response to 401 
treatment failure or side effects [13]. Therefore, measuring adherence to any 402 
antihypertensive drug therapy (therapy adherence), in this current study, helped to avoid 403 
PLVXQGHUVWDQGLQJ RI SDWLHQWV¶ medication-taking behaviours toward a particular 404 
antihypertensive drug class and provided more insights.  405 
 406 
Additionally, the model generated from using GLM method in this study could potentially be 407 
applied as a predication tool for identifying patients at risks of poor adherence who could 408 
possibly then be targeted for adherence improving interventions; however, this requires 409 
further validation and evaluation research.  410 
 411 
However, a number of limitations need to be acknowledged. Although a wide range of 412 
demographics and clinically related factors were considered in this study, bias due to 413 
unmeasured confounders, such as dosing history, cannot be ruled out due to the 414 
retrospective nature of the study design. Although some of the antihypertensive drugs could 415 
be used to treat other conditions alongside hypertension, the criterion of antihypertensive 416 
GUXJV¶ SUHVFULSWLRQ GDWH DOZD\V EHLQJ RQ RU DIWHU WKH K\SHUWHQVLRQ GLDJQRVLV GDWH KDV417 
ensured that treating hypertension ZDVDWOHDVWRQHRIWKHGUXJ¶VSRWHQWLDOLQGLFDWLRQV. 418 
 419 
In addition, the CPRD contains only prescribed data, therefore adherence was measured 420 
indirectly by PDC as a proxy, which may lead to further overestimation of medication 421 
adherence. Furthermore, overestimation of adherence might have resulted also from 422 
excluding patients on multiple therapies at the index date as they might have higher risk of 423 
poor adherence. 424 
 425 
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Another limitation, which applies to any secondary database analysis, includes measuring 426 
adherence using secondary databases. This has been validated with other methods of 427 
DGKHUHQFH PHDVXUHPHQW VXFK DV HOHFWURQLF GHYLFHV SDWLHQWV¶ VHOI-reports and pill counts 428 
[52, 53], and no substantial differences between dispensing and prescribing datasets were 429 
found [54]. Given the different methods to measure medication adherence using secondary 430 
databases, it could be argued that each method may produce different results. However, 431 
Hess et al (2006) [55] in their comparison of the various methods of measuring adherence 432 
using secondary databases found that all the methods provide comparable values.  433 
 434 
Among the adherence measures, medication possession ratio (MPR) and PDC were the 435 
EHVWSUHGLFWRUVRISDWLHQWV¶KRVSLWDOLVDWLRQV [56]. PDC is considered preferable than MPR as 436 
it provides more conservative estimates of adherence, especially in the presence of 437 
therapeutic switching or concurrent drug therapy [57, 58], even though adherence alone 438 
does not provide information on whether patients benefit from the increased use of 439 
medicines.  440 
  441 
Conclusions 442 
Overall, adherence to antihypertensive medications was suboptimal among patients with 443 
primary hypertension. A set of patient-level factors has been identified as potential 444 
GHWHUPLQDQWVIRUSDWLHQWV¶Ddherence to antihypertensive drugs that would potentially assist 445 
to identify patients at risk of poor adherence. Subsequently, those patients can be targeted 446 
for adherence improving interventions and/or more intensive follow-up by healthcare 447 
professionals to improve their adherence level.  448 
 449 
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Tables  
Table 1. Patient characteristics at first-ever antihypertensive drug class episodes 
Covariates ACEIs CCBs Diuretics BBs ARBs ³2WKHUV´ Total  
Number of episodes (%) 110,493 (29.7) 93,119 (25.1) 71,883 (19.3) 42,164 (11.4) 39,862 (10.7) 14,084  (3.8) 371,605  
Mean age (±SD) years 57.9±12.4 64.8±12.0 67.4±12.1 61.5±13.1 62.2±12.6 64.7±14.1 62.2±12.9 
Gender (%)a        
Male  61,655 (55.8) 46,839 (50.3) 23,865 (33.2) 17,709 (42.0) 18,695 (46.9) 6,648 (47.2) 177,627 (47.8) 
Female 48,838 (44.2) 46,280 (49.7) 48,018 (66.8) 24,455 (58.0) 21,167 (53.1) 7,436 (52.8) 193,978 (52.2) 
Townsend deprivation score (quintile) (%)b        
1 (Least deprived) 28,176 (25.5) 22,535 (24.2) 17,252 (24.0) 11,131 (26.4) 11,042 (24.5) 3,451 (24.5) 97,361 (26.2) 
2 26,739 (24.2) 22,162 (23.8) 17,539 (24.4) 10,372 (24.6) 10,045 (25.2) 3,324 (23.6) 86,212 (23.2) 
3 22,983 (20.8) 18,996 (20.4) 15,455 (21.5) 8,728 (20.7) 81,72 (20.5) 3,042 (21.6) 73,578 (19.8) 
4 19,889 (18.0) 17,227 (18.5) 13,298 (18.5) 7,547 (17.9) 6,418 (16.1) 2,577 (18.3) 63,544 (17.1) 
5 (Most deprived) 12,707 (11.5) 12,292 (13.2) 8,338 (11.6) 4,385 (10.4) 4,186 (10.5) 1,648 (11.7) 50,910 (13.7) 
Median follow up time (IQR, years)b 4.6 (2.9, 6.4) 4.4 (2.6, 6.4) 5.6 (3.6, 6.9) 6.8 (4.6, 7.0) 6.5 (4.4,6.9) 6.5 (4.2, 6.9) 5.1 (3.2, 6.8) 
CCI (%)a 
     
  
0 65,412 (59.2) 58,292 (62.6) 44,208 (61.5) 30,400 (72.1) 22,522 (56.5) 7,535 (53.5) 229,280 (61.7) 
1 24,529 (22.0) 18,251 (19.6) 14,520 (20.2) 6,072 (14.4) 9,288 (23.3) 3,451 (24.5) 75,807 (20.4) 
 20,552 (18.6) 16,575 (17.8) 13,155 (18.3) 5,692 (13.5) 8,052 (20.2) 3,098 (22.0) 66,517 (17.9) 
Hypertension status (%)a        
Incident cases 62,650 (56.7) 51,960 (55.8) 26,165 (36.4) 7,252 (17.2) 6,458 (16.2) 2,225 (15.8) 165,364 (44.5) 
Prevalent cases 47,843 (43.3) 41,159 (44.2) 45,718 (63.6) 34,912 (82.8) 33,404 (83.8) 11,859 (84.2) 206,241 (55.5) 
Drug use status (%)a        
Incident users 72,925 (66.0) 60,993 (65.5) 29,184 (40.6) 9,698 (21.0) 9,328 (23.4) 3,606 (25.6) 193,978 (52.2) 
Prevalent users 37,568 (34.0) 32,126 (34.5) 42,699 (59.4) 33,310 (79.0) 30,534 (76.6) 10,478 (74.4) 177,627 (47.8) 
(Note) a p<0.001 from McNemar test; b p<0.001 Kruskal-Wallis test; IQR: interquartile range; CCI: Charlson comorbidity index; ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin 
receptor blockers; CCBs: calcium channel blockers; BBs: beta-blockers 
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Table 2. Univariate analysis of the patient related factors with class and therapy PDC 
Covariates 
Class PDC  Therapy PDC 
Statistical test 
Median (IQR) p-value  Median (IQR) p-value 
Index drug class 
 
     
ACEIs 95.7 (51.3, 100) 
 
 98.3 (85.8, 100) 
  
CCBs 94.3 (50.4, 100) 
 
 98.6 (86.5, 100) 
  
Diuretics 90.6 (44.2, 100) P=0.001  97.8 (85.9, 100) P=0.0001 Kruskal-Wallis test 
BBs 86.7 (24.3, 100) 
 
 98.5 (88.0, 100) 
  
ARBs 97.4 (74.2, 100) 
 
 98.3 (88.7, 100) 
  
³2WKHUV´ 84.4 (26.7, 100) 
 
 98.5 (86.8, 100) 
  
Gender  
 
  
 
  
Male  94.2 (51.1,100) P<0.001  97.9 (85.7, 100) P<0.001 
Wilcoxon rank sum 
(Mann-Whitney) test 
Female 93.6 (43.7, 100) 
 
 98.7 (87.2, 100) 
  
Townsend deprivation 
score (quintile) 
      
1 (Least deprived) 95.3 (48.3, 100)   98.8 (89.4, 100)   
2 94.6 (47.8, 100)   98.6 (88.2)  Kruskal-Wallis test 
3 94.2 (47.7, 100) P=0.001  98.3 (86.8, 100) P=0.0001  
4 93.0 (46.9, 100)   97.9 (84.1, 100)   
5 (Most deprived) 89.6 (45.1, 100)   96.6 (78.1, 100)   
Drug use status  
 
     
Wilcoxon rank sum  
(Mann-Whitney) test 
Incident users 92.7 (37.9, 100) P<0.001  98.2 (82.7, 100) P<0.001 
Prevalent users 94.9 (57.0, 100) 
 
 98.4 (89.4, 100) 
 
Hypertension status       
Wilcoxon rank sum  
(Mann-Whitney) test 
Incident cases 93.3 (39.3, 100) P<0.001  98.5 (84.0, 100) P= 0.0079 
Prevalent  cases 94.3 (53.1, 100)   98.2 (88.0, 100)  
Switching index drug       
Wilcoxon rank sum 
(Mann-Whitney) test 
No NA NA  98.7 (88.9, 100) P<0.001 
Yes 
  
 96.7 (78.4, 100) 
 
CCI 
 
  
 
 
Kruskal-Wallis test 
0 93.7 (45.5, 100) 
 
 98.1 (85.8, 100) 
 
1 94.3 (50.6, 100) P=0.001  98.5 (87.1, 100) P=0.0001 
 94.3 (49.1, 100) 
 
 98.9 (87.7, 100) 
 
Age (years) 0.08* P<0.001  0.15* P<0.001 
6SHDUPDQ¶VUDQN
correlation test  
Follow up time (years) 0.03* P<0.001  0.02* P<0.001 
6SHDUPDQ¶VUDQN
correlation test  
(Note) PDC: proportion days covered; IQR: interquartile range ; ACEIs: angiotensin converting enzyme inhibitors; ARBs: 
angiotensin receptor blockers; CCBs: calcium channel blockers; BBs: beta-blockers; CCI: Charlson comorbidity index; NA: 
not applicable  
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Table 3. Results from the GLM regression of the patient related factors with class 
and therapy adherence  
Covariates 
Class PDC  Therapy PDC 
Coefficients (95%CI) p-value  Coefficients (95%CI) p-value 
Index drug class 
  
 
  
Diuretics 1.0 
 
 1.0 
 
ACEIs 0.08 (0.074, 0.087) <0.001  0.04 (0.035, 0.043) <0.001 
CCBs 0.052 (0.04, 0.06) <0.001  0.02 (0.017, 0.025) <0.001 
BBs -0.09 (-0.10, 0.-0.084) <0.001  0.016 (0.011, 0.020) <0.001 
ARBs 0.13 (0.12, 0.14) <0.001  0.03 (0.023, 0.032) <0.001 
³2WKHUV´ -0.11(-0.13, -0.09) <0.001  -0.008 (-0.011, 0.0096) 0.869 
Gender  
  
 
  
Male  1.0 
 
 1.0 
 
Female -0.034 (-0.38, -0.029) <0.001  0.004 (0.0012, 0.0060) <0.001 
Townsend deprivation score (quintile)      
1 (Least deprived) 1.0   1.0  
2 -0.003 (-0.009, 0.002) 0.294  -0.009 (-0.012, -0.01) <0.001 
3 -0.002 (-0.009, 0.004) 0.452  -0.013 (-0.02, 0.01) <0.001 
4 -0.008 (-0.012, -0.001) 0.022  -0.025 (-0.03, -0.02) <0.001 
5 (Most deprived) -0.02 (-0.03, -0.01) <0.001  -0.05 (-0.06, -0.04 <0.001 
Drug use status  
  
 
  
Incident users 1.0 
 
 1.0 
 
Prevalent users 0.13 (0.12, 0.14) <0.001  0.06 (0.055, 0.065) <0.001 
Hypertension status  
  
 
  
Incident cases 1.0 
 
 1.0 
 
Prevalent  cases 0.02 (0.008, 0.025) 0.02  0.03 (0.028, 0.04) <0.001 
CCI  
  
 
  
0 1.0 
 
 1.0 
 
1 0.0006 (-0.0049, 0.006) 0.837  0.03 (-0.00002, 0.0059) 0.052 
 -0.02 (-0.021, -0.0092) <0.001  -0.046 (-0.078, - 0.0020) 0.004 
Age (years) 0.003 (0.0028, 0.0033) <0.001  0.0032 (0.0032, 0.0033) <0.001 
Follow up time (years) -0.014 ( -0.016, -0.013) <0.001  0.007 (0.006, 0.0073) <0.001 
Follow up time categories (years)      
 1.0   1.0  
>2-3 -0.017 (-0.022, -0.012) <0.001  -0.08 (-0.14, -0.03) 0.001 
>3-4 -0.024 (-0.030, -0.019) <0.001  -0.04 (-0.09, 0.01) 0.148 
>4-5 -0.035 (-0.040, -0.030) <0.001  -0.02 (-0.07, 0.03) 0.756 
>5 -0.035 (-0.039, -0.030) <0.001  0.18 (0.21, 0.14) <0.001 
Switching index drug 
NA NA 
 
  
No  1.0 
 
Yes  -0.043 (-0.046, -0.040) <0.001 
(Note) PDC: proportion days covered; ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; 
CCBs: calcium channel blockers; BBs: beta-blockers; CCI: Charlson comorbidity index; NA: not applicable  
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Figures 
Figure 1 Cumulative proportion of patientV¶ adherence to any antihypertensive drug 
therapy 
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Figure 2 Cumulative proportion of adherence of the episodes of the six 
antihypertensive drug classes 
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